ESMO 2019: Merck unveils neoadjuvant/adjuvant TNBC trial results

Keytruda is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. Credit: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.



  • ESMO